Priothera Presents Groundbreaking Research on Mocravimod
Mocravimod is showcasing its potential as a revolutionary treatment in the ongoing global MO-TRANS Phase 3 study targeted at patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation.
Priothera Ltd., a dynamic biopharmaceutical firm, is at the forefront of this transformation in cancer care, committed to using its oral sphingosine 1 phosphate (S1P) receptor modulator, mocravimod, to enhance treatment approaches in hematologic malignancies.
The MO-TRANS study, currently unrolling in multiple centers, is pivotal as it evaluates both the efficacy and safety of mocravimod as an adjunctive and maintenance therapy for patients diagnosed with AML, particularly those preparing for allo-HCT.
Innovative Approach of Mocravimod
Mocravimod stands out as the only S1P receptor modulator aimed at addressing the complexities of blood cancers. Its novel dual mechanism of action is tailored to improve treatment outcomes by enhancing the graft-versus-leukemia (GvL) effect. This mechanism works by retaining donor T-cells within lymphoid organs, thereby amplifying their effect on cancer cells while simultaneously minimizing the occurrence of graft-versus-host disease (GvHD).
Understanding the MO-TRANS Phase 3 Study
The MO-TRANS Phase 3 study has been designed as a multicenter, global, placebo-controlled clinical trial. It targets patients with AML who are in complete remission (CR1), including those at intermediate or high risk. The study will also include patients with a second complete remission (CR2). Recruitment allows for a balanced comparison between patients receiving mocravimod and those receiving a placebo, both alongside standard care practices.
Primary metrics for assessing the trial's success include relapse-free survival (RFS), and secondary metrics will evaluate overall survival (OS) as well as the incidence rates of GvHD.
Presentation Details at ASH Annual Meeting
As part of its participation in the American Society of Hematology (ASH) Annual Meeting, Priothera is set to share the latest findings from the MO-TRANS study. The presentation is scheduled for December 9, 2024, where Dr. Gabriela Sanchez-Petitto, a prominent hematologist and assistant professor, will discuss the data.
Details regarding the presentation include:
- Title: MO-TRANS: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Mocravimod (MOC) as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
- Presenter: Dr. Gabriela Sanchez-Petitto, MD.
- Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III.
- Date & Time: December 9, 2024, 6:00 PM–8:00 PM PT.
About Mocravimod and Priothera
Mocravimod is positioned to fill a substantial gap in the treatment of AML during transplant procedures. By focusing on enhancing the GvL effect while mitigating GvHD risk, mocravimod serves a critical need in oncology care.
Priothera, founded in 2020, has its roots in France, operating with a goal to establish mocravimod as a standard adjunctive therapy for hematologic cancers. The embodiment of innovative healthcare, it is driven by a team with vast experience in hemato-oncology and cell-based treatments, supported by renowned international investors.
Frequently Asked Questions
What is mocravimod?
Mocravimod is a synthetic S1P receptor modulator designed to treat acute myeloid leukemia and improve outcomes for patients undergoing transplantation.
What is the MO-TRANS study?
The MO-TRANS study is a global Phase 3 clinical trial evaluating mocravimod's effectiveness and safety in AML patients preparing for allogeneic hematopoietic cell transplantation.
When will the results of the MO-TRANS study be presented?
The presentation is set for December 9, 2024, during the ASH Annual Meeting, with Dr. Gabriela Sanchez-Petitto as the presenter.
Why is mocravimod unique?
Mocravimod is the only S1P receptor modulator specifically being developed for adjunctive treatment in blood cancers, providing a unique therapeutic approach.
Where is Priothera headquartered?
Priothera operates its headquarters in Dublin, Ireland, with a focus on advancing treatments for hematologic malignancies.
